SURGI-BOW - Early Surgery Versus 3 Days Non-surgical Management in Acute Small Bowel Obstruction: a Randomized Open-label Controlled Study
SURGI-BOW - Early Surgery Versus 3 Days Non-surgical Management in Acute Small Bowel Obstruction: a Randomized Open-label Controlled Study
For uncomplicated acute small bowel obstruction (aSBO), the "Bologna guidelines" recommend non-surgical management of 72 hours before considering surgery. This treatment is based on the placement of a nasogastric tube and the correction of hydro-electrolyte disorders. Non-surgical management is only effective in 60 to 70% and surgery is therefore necessary in 30 to 40% of cases after medical treatment for at least 3 days. This therefore leads to an increase in the length of hospital stay. Some authors also point out that postponing surgery for 3 days would aggravate the morbidity and mortality of surgery. Indeed, aSBO surgery has a complication rate of 10-40% and a mortality of up to 4%.
There is a lack of studies evaluating what is the best management strategy for aSBO, especially with regard to the duration of medical treatment. Many recent studies plead in favor of early surgical treatment (<24 hours) which would reduce the morbidity and mortality rate of surgery but also the overall cost of treatment by reducing the length of stay.
This paradigm shift is linked to the improvement of anesthetic and intensive care management over the last few years, but also to the advent of laparoscopy in emergency surgery. Indeed, laparoscopy could reduce the duration of hospitalization but also the operative morbidity and mortality. However, this surgical approach is not feasible in all situations and the conversion rate is reported in 30 to 76% of cases. One of the factors favoring the feasibility of the laparoscopic approach is the performance of early surgery.
Another parameter favoring the feasibility of the laparoscopic approach is the aSBO mechanism: an aSBO on flange (SBA) is more likely to be treated effectively by laparoscopic than an aSBO on multiple adhesions (MA).
In the literature, there is little to differentiate SBAs from MAs. Advances in CT scans have made it possible to describe the signs associated with the SBA mechanism and then to propose a score making it possible to predict the SBA mechanism with good performance (sensitivity 67.6%, specificity 84.6%). This score not only has the advantage of predicting the mechanism of the occlusion but it also makes it possible to predict the failure of non-surgical treatment if the score is ≥5.
Multicentre randomized open-label controlled trial. Patients admitted to visceral surgery for aSBO are screened and the study is offered for patients who do not meet the criteria for emergency surgery.
If they accept the study, a randomization is carried out by stratification according to (i) the sex, (ii) the center (University hospital/ Peripheral center), (iii) the number of previous episodes of aSBO (0 or ≥1 ) and the value of the radiological score (< or ≥5).
Patients are cared for according to the strategy defined by randomisation (standard procedure vs early surgery proposed according to the radiological score). Demographic information, medical and surgical history, and treatments are collected on the day of admission.
A visit is made each day (from admission to discharge) to collect information on the surgery (if performed), on the medical management and its success or failure (if applicable), on the recovery of functions gastrointestinal, on perioperative management, on morbidity and mortality.
Patients have a follow-up consultation on D30 and D90 postoperative. Any morbidity, mortality or recurrence that occurred during this period is collected.
Patients are contacted by telephone after 12 months to ensure that no recurrence of aSBO has occurred.
Inclusion Criteria:
Exclusion Criteria:
Paul.LeNaoures@chu-angers.fr(0)2 41 35 49 16 ext. 33
AuVenara@chu-angers.fr(0)2 41 35 36 18 ext. 33
Amiens, 80054, France
regimbeau.jean-marc@chu-amiens.fr3 22 08 89 00 ext. 33
aurelien.venara@chu-angers.fr2 41 35 49 16 ext. 33
bogdan.badic@chu-brest.fr2 98 34 72 35 ext. 33
m.ouaissi@chu-tours.fr2 18 37 05 75 ext. 33
Marine.SarfatiLebreton@chu-angers.fr2 43 09 33 55 ext. 33
pablo.ortega-deballon@chu-dijon.fr3 80 29 37 47 ext. 33
egirard1@chu-grenoble.fr4 76 76 54 65 ext. 33
emeric.abet@ght85.fr2 51 44 61 61 ext. 33
fr-souche@chu-montpellier.fr4 67 33 70 72 ext. 33
emilie.duchalais@chu-nantes.fr2 40 08 33 33 ext. 33
massalou.d@chu-nice.fr4 92 03 77 77 ext. 33
guillaume.passot@chu-lyon.fr4 78 86 23 71 ext. 33
Fabien.ROBIN@chu-rennes.fr2 99 28 90 37 ext. 33
cecile.brigand@chru-strasbourg.fr3 88 12 72 26